INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS
https://doi.org/10.20996/1819-6446-2008-4-5-85-90
Abstract
Mechanisms of renal disorders in cardiovascular diseases are presented. The main of these mechanisms is an endothelium dysfunction. It is related with some factors: arterial hypertension, insulin resistance syndrome, diabetes type 2, dyslipidemia, obesity. Approaches to prevention of kidney disorder and cardiovascular complications are discussed with focus on usage of angiotensin II receptor blockers.
About the Author
V. V. Fomin
Moscow Medical Academy named after M.I. Setchenov, Rossolimo ul., 11-a, Moscow, 119881 Russia
Russian Federation
Chair of Therapy and Occupational Diseases
Russian Federation
Chair of Therapy and Occupational Diseases
References
1. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004;(6):39– 46.
2. Мухин Н.А. Снижение скорости клубочковой фильтрации – общепопуляционный маркер неблагоприятного прогноза. Тер арх 2007;(6):5–10.
3. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
4. Комитет экспертов Всероссийского научного общества кардиологов и Научного общества нефрологов России. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика 2008;7(6 приложение 3):3- 24.
5. De Jong P.E., Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004;66(6):2109–18.
6. Ochodnicky P., Henning R.H., van Dokkum R.P., de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006;47 Suppl 2:S151-62
7. Tsakiris A., Doumas M., Lagatouras D. et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology. 2006; 57(3):313–20.
8. Metclaf P., Baker J., Scott A. et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin Chem 1992;38(9):1802-8.
9. . Shankar S.S., Steinberg H.O. Obesity and endothelial dysfunction. Semin Vasc Med 2005;5(1):56–64.
10. Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер арх 2005;(5):36–41.
11. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S. et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19(8):1992-7.
12. Lieb W., Mayer B., Stritzke J. et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006;21(10):2780–7.
13. Wachtell K., Palmieri V., Olsen M.H. et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002;143(2):319–26.
14. Munakata M., Nunokawa T., Yoshinaga K. et al. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension - a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 2006; 29(7):515–21.
15. Земченков А.Ю., Томилина Н.А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Реко- мендаций K/DOQI по диагностике, классификации и оценке тя- жести хронических заболеваний почек). Нефрология и диализ 2004;6(3):204–20.
16. Meguid El Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005;365(9456):331–40.
17. Clase C.M., Garg A.X., Kiberd B.A. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13(5):1338-49.
18. Bibbins-Domingo K., Chertow G.M., Fried L.F. et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006;166(13):1396- 402.
19. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика; 2004. 20. Фомин В.В., Моисеев С.В., Мухин Н.А. Артериальная гипертония высокого риска: место блокаторов рецепторов ангиотензина II. Тер арх 2007;(10):86-91.
20. Lindholm L., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):1004-10.
21. Brown B., Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 18(9 Pt 2):127S-133S.
22. Rodby R.A., Rohde R.D., Clarke W.R. et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000;15(4):487–97.
23. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851– 60.
24. Berl T., Hunsicker L.G., Lewis J.B. et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138(7):542-9.
25. Pohl M.A., Blumenthal S., Cordonnier D.J. et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005;16(10):3027-37.
26. Berl T., Hunsicker L.G., Lewis J.B. et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16(7):2170-9. 28. Anavekar N.S., Gans D.J., Berl T. et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004;(92):S50-S55.
27. Atkins R.C., Briganti E.M., Lewis J.B. et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45(2):281-7.
28. Bramlage P., Pittrow D., Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004;20(10):1625-31.
29. Schmieder R.E., Krekler M. Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ [inGerman]. MMW Fortschr Med. 2005;147 Suppl 3:97- 101.
30. Parving H.H., Lehnert H., Br chner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–8.
31. Opie L.H., Parving H.H. Diabetic nephropathy. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation 2002;106:643–5.
Review
For citations:
Fomin V.V. INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS. Rational Pharmacotherapy in Cardiology. 2008;4(5):85-90. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-5-85-90
Views:
515
Email this article 